metaPreg - Gabapentin (Epilepsy) during pregnancy

Gabapentin (Epilepsy)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.34 [0.42, 4.34]	0%	5 studies	97	84	not evaluable	ROB	-
Major congenital malformations	1.48 [0.46, 4.79]	0%	5 studies	92	84	serious	ROB	-
Atrial septal defect	-	-	0 study					-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	10.63 [0.54, 209.24]	0%	2 studies	4	3	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	-	-	0 study					-
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	4.41 [0.49, 39.98]	0%	3 studies	3	17	not evaluable	ROB	-
Early intrauterine death (< 22 weeks)	4.64 [0.23, 93.20]	0%	2 studies	2	3	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	7.99 [0.44, 143.69]	0%	2 studies	6	2	not evaluable	ROB	-
5 non statistically significant endpoints reported in only one study